• Skip to content
  • Accessibility help
Skip to content
Sign in
  • Guidance
  • Skip Standards and indicators submenu

    Quality standards

    Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.

    View our quality standards

    • How to use our quality standards
    • The timeline for developing quality standards
    • Help us develop quality standards
    • Selecting and prioritising quality standards topics
    • About quality standards

    Indicators

    Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.

    View list of indicators

    • Learn about the committee that develops indicators
    • About indicators
  • Skip Life sciences submenu

    Life Sciences

    We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.

    View life sciences

    Get support from NICE

    NICE Advice service

    Trusted, unrivalled expertise.

    Make an enquiry

    Contact us to discuss your requirements.

    Innovative Licensing and Access Pathway (ILAP)

    Streamlining patient access to safe, financially sustainable and innovative medicines.

    Learn how we evaluate technologies

    Health technology evaluation and topic selection manuals

    Updated manuals for methods, processes and topic selection.

    Digital health technologies

    Accelerating our efforts to deliver innovation to the health and care system.

    Evidence standards framework

    Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.

    Our guidance programmes

    Ensuring new technologies are clinically effective and offer economic value.

    Register your product

    Non-pharmaceutical

    NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.

    Pharmaceutical

    UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.

    Find published and proposed evaluations

    Diagnostics

    Guidance on measurements and tests used to evaluate a patient's condition.

    Medical technologies

    Guidance on medical technologies put forward to NICE by manufacturers.

    Technology appraisals

    Guidance on new and existing medicines and treatments in the NHS.

    Highly specialised technologies

    Guidance on the use of highly specialised medicines and treatments.

  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Clinical Knowledge Summaries (CKS)
  • Skip About submenu

    About

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

    Explore about

    Our programmes

    Learn about the information we produce.

    • Guidance
    • Advice
    • Quality standards
    • Indicators
    • Digital health
    • Topic selection

    Get involved

    • Understand how decisions are made:

      Attend a committee meeting
    • Comment on draft guidance:

      Guidance in consultation
    • Be part of a guidance committee:

      Join a committee
    • Help develop our products:

      Register as a stakeholder
    • Putting you at the heart of our work:

      Public involvement

    What we do

    • Social care
    • Life sciences
    • NICE international
    • Patient safety
    • Shared decision making
    • View all What we do

    Into practice

    • Social care quick guides
    • Measuring the use of NICE guidance
    • Resource planner
    • View all Into practice

    Who we are

    • The board
    • The NICE strategy 2021 to 2026
    • Corporate publications
    • View all Who we are

    • Contact us
    • Jobs

My account

  • Consultation responses
  • Sign in

You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Eye conditions

Serious eye disorders

  • Quality standard
  • Reference number: QS180
  • Published:  12 February 2019
  • Quality standard
  • Tools and resources
  • History
Download (PDF)
  • Overview
  • Quality statements
  • Quality statement 1: Referral – chronic open angle glaucoma and related conditions
  • Quality statement 2: Referral for cataract surgery
  • Quality statement 3: Treatment – late age-related macular degeneration (wet active)
  • Quality statement 4: Monitoring late age-related macular degeneration (wet active)
  • Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
  • Quality statement 6: Certificate of vision impairment
  • Update information
  • About this quality standard

On this page

  1. Quality statement
  2. Rationale
  3. Quality measures
  4. What the quality statement means for different audiences
  5. Source guidance
  6. Definitions of terms used in this quality statement

Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions

Quality statement

Adults with chronic open angle glaucoma (COAG) or related conditions have reassessment at specific intervals.

Rationale

Reassessment is important for identifying clinically significant changes in adults with COAG or adults at risk of conversion from ocular hypertension (OHT) or suspected COAG to COAG. Reassessment also supports maintaining a consistent intraocular pressure (IOP). Providing tailored treatment in response to disease progression and maintaining IOP levels reduces the risk of significant sight loss, and reduced quality of life.

Quality measures

The following measures can be used to assess the quality of care or service provision specified in the statement. They are examples of how the statement can be measured, and can be adapted and used flexibly.

Structure

Evidence of local arrangements to ensure that adults with COAG or related conditions have reassessment appointments scheduled at specific intervals, according to their risk of conversion to COAG or progression to sight loss.

Data source: No routinely collected national data for this measure has been identified. Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, service specifications and local protocols.

Process

a) Proportion of adults with COAG or related conditions who have reassessment at specific intervals.

Numerator – the number in the denominator who have reassessment at specific intervals.

Denominator – the number of adults with COAG or related conditions.

Data source: No routinely collected national data for this measure has been identified. Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, patient records and appointment systems.

b) Proportion of scheduled reassessment appointments for COAG or related conditions that are cancelled or delayed by the service provider.

Numerator – the number in the denominator that are cancelled or delayed by the service provider.

Denominator – the number of scheduled reassessment appointments for COAG or related conditions.

Data source: No routinely collected national data for this measure has been identified. Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, patient records and appointment systems.

c) Proportion of hospital appointments for adults with COAG or related conditions that occur within 25% of their intended reassessment period, including rescheduling of hospital cancellations and non-attendance by adults with COAG or related conditions.

Numerator – the number in the denominator that occur within 25% of their intended reassessment period.

Denominator – the number of reassessment appointments scheduled, including those rescheduled after hospital-initiated cancellation and non-attendance by adults with COAG or related conditions.

Data source: NHS England's Elective care transformation programme: Transforming elective care services: ophthalmology includes an indicator in this area. Local data collection, for example, clinic attendance and cancellation records.

Outcome

a) Loss of vision for adults with COAG or related conditions (visual field loss, changes to visual acuity).

Data source: Database audit – National Electronic Glaucoma Surgery and Visual Field Preservation Audit feasibility report contains: rates of visual field loss in the worst eyes (figure 44), speed of visual field progression (figure 45), and loss of sight years (table 11). Data were last collected in 2015 from 5 major glaucoma centres. Available from the Royal College of Ophthalmologists' National Ophthalmology Database Audit.

Local data collection, for example, patient records and local ophthalmology records of patient safety incidents.

b) Health-related quality of life for adults with COAG or related conditions.

Data source: No routinely collected national data for this measure has been identified. Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, a questionnaire.

What the quality statement means for different audiences

Service providers (NHS hospital trusts and community optometry services) have agreed protocols to ensure that adults with COAG or related conditions have reassessment at specific intervals, according to their risk of progressive sight loss.

Healthcare professionals (such as ophthalmologists, advanced nurse practitioners, optometrists and orthoptists) carry out reassessment for adults with COAG or related conditions at specific, clinically appropriate intervals, according to their risk of progressive sight loss.

Commissioners (clinical commissioning groups) ensure that services provide reassessment for adults with COAG or related conditions at specific intervals, according to their risk of progressive sight loss.

Adults with glaucoma, suspected glaucoma or ocular hypertension have regular assessments to minimise their risk of sight loss. How often they have an assessment will depend on how well the treatment seems to be working.

Source guidance

Glaucoma: diagnosis and management. NICE guideline NG81 (2017, updated 2022), recommendations 1.5.9, 1.5.11, 1.5.12 and 1.5.13

Definitions of terms used in this quality statement

Specific intervals for reassessment of COAG or related conditions

Specific intervals for reassessment depend on the risk of progression to sight loss, as set out in tables 1 to 3 in NICE's guideline on glaucoma. Clinical judgement is used to decide when the next appointment should take place within the recommended interval.


Next page Quality statement 6: Certificate of vision impairment Previous page Quality statement 4: Monitoring late age-related macular degeneration (wet active)
Back to top
  • Guidance
  • Standards and indicators
  • Life sciences
  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Clinical Knowledge Summaries (CKS)
  • Knowledge resources
  • About NICE
  • Into practice
  • Get involved with NICE
  • Jobs
  • News
  • Newsletters and alerts
  • Contact us
  • Leave feedback
  • Reusing our content
  • NICE UK Open Content Licence
  • Syndicate our content
  • Events
  • Facebook
  • X
  • YouTube
  • LinkedIn
  • Accessibility
  • Freedom of information
  • Glossary
  • Terms and conditions
  • Privacy notice
  • Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.